<p>药明康德（NASDAQ:BMRN - 获取免费报告）的股票在周二由 Wedbush 重新发布了 “跑赢大盘” 的评级，RTT 新闻报道。他们目前对这家生物技术公司的股票设定了 94.00 美元的目标价。Wedbush 的目标价意味着该股票当前价格有 51.02% 的潜在上涨空间。</p>
<ul>
<li>药明康德的股票能否满足华尔街的高期望？</li>
</ul>
<p>其他一些股票研究分析师最近也对该股票发布了报告。Wolfe Research 在 7 月 15 日的研究报告中对药明康德的股票设定了 95.00 美元的价格目标，并给予公司 “跑赢大盘” 的评级。Wall Street Zen 在 7 月 18 日的研究报告中将药明康德的股票评级从 “强力买入” 下调至 “买入”。高盛集团在 5 月 5 日的研究报告中将药明康德的股票目标价从 124.00 美元下调至 104.00 美元，并给予公司 “买入” 评级。摩根士丹利在 7 月 22 日的报告中将药明康德的目标价从 97.00 美元下调至 96.00 美元，并给予公司 “增持” 评级。最后，摩根大通在 7 月 14 日的研究报告中将药明康德的股票目标价从 108.00 美元上调至 113.00 美元，并给予该股票 “增持” 评级。六位股票研究分析师对该股票给予了持有评级，十九位分析师给予公司买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 93.78 美元。</p>
<p><strong>获取我们对 BMRN 的最新股票分析</strong></p>
<h2>药明康德的价格表现</h2>
<ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
<p>周二，BMRN 的交易价格上涨了 1.93 美元，达到 62.24 美元。该股票的交易量为 1,233,643 股，而其平均交易量为 1,887,433 股。该公司的市值为 119.4 亿美元，市盈率为 23.21，市盈率/增长比率为 0.80，贝塔值为 0.18。药明康德的 1 年最低价为 52.93 美元，1 年最高价为 94.85 美元。该公司的债务与股本比率为 0.10，流动比率为 5.52，速动比率为 3.49。该公司的 50 日移动平均价格为 57.16 美元，200 日移动平均价格为 61.79 美元。</p>
<h2>药明康德的内部交易</h2>
<p>在相关消息中，首席会计官 Erin Burkhart 在 5 月 20 日的交易中出售了 1,786 股药明康德的股票。该股票以平均价格 59.31 美元出售，总交易额为 105,927.66 美元。出售完成后，首席会计官持有该公司 14,173 股股票，价值 840,600.63 美元。此次交易使其持股减少了 11.19%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。内部人士持有该公司 0.85% 的股票。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
<p>一些对冲基金最近买入和卖出了该公司的股票。Rise Advisors LLC 在第一季度购买了药明康德的新头寸，价值 30,000 美元。Farther Finance Advisors LLC 在第一季度将其在药明康德的股份增加了 95.9%。Farther Finance Advisors LLC 现在拥有 431 股该生物技术公司的股票，价值 29,000 美元，此前在该期间又购买了 211 股。V Square Quantitative Management LLC 在第二季度购买了药明康德的新头寸，价值约 25,000 美元。LRI Investments LLC 在第四季度将其在药明康德的股份增加了 856.9%。LRI Investments LLC 现在拥有 488 股该生物技术公司的股票，价值 32,000 美元，此前在上个季度又购买了 437 股。最后，MassMutual Private Wealth &amp; Trust FSB 在第一季度将其在药明康德的股份增加了 71.2%。MassMutual Private Wealth &amp; Trust FSB 现在拥有 524 股该生物技术公司的股票，价值 37,000 美元，此前在该期间又购买了 218 股。98.71% 的股票目前由机构投资者持有。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德公司开发和商业化针对严重和危及生命的罕见疾病及医疗状况的治疗方案。其商业产品包括 Vimizim，一种用于治疗粘多糖贮积症（MPS）IV 型 A 的酶替代疗法；Naglazyme，一种用于 MPS VI 患者的重组 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的专有合成口服 6R-BH4。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>国会股票交易跟踪</li>
<li>Figma 的疯狂 IPO 之旅：股票的溢价价格是否合理？</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>META 获得巨大升级：分析师认为股票可能上涨多少</li>
<li>投资旅游股票的好处</li>
<li>诺和诺德股票下跌——但是否终于触底？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而拜玛林制药并不在名单上。</p>
<p>虽然拜玛林制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

拜玛林制药

<p>Wedbush 重申了对拜玛林制药（BioMarin Pharmaceutical，股票代码：BMRN）的 “跑赢大盘” 评级，目标价为 94.00 美元，意味着潜在上涨空间为 51.02%。其他分析师也给出了评级，Wolfe Research 设定了 95.00 美元的目标价，高盛则将其调整至 104.00 美元。该股票目前交易价格为 62.24 美元，市场共识评级为 “适度买入”，平均目标价为 93.78 美元。拜玛林专注于罕见疾病的治疗，市值为 119.4 亿美元</p>

<p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by Wedbush in a note issued to investors on Tuesday,RTT News reports. They presently have a $94.00 target price on the biotechnology company's stock. Wedbush's target price points to a potential upside of 51.02% from the stock's current price.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:BMRN - 获取免费报告）的股票在周二由 Wedbush 重新发布了 “跑赢大盘” 的评级，RTT 新闻报道。他们目前对这家生物技术公司的股票设定了 94.00 美元的目标价。Wedbush 的目标价意味着该股票当前价格有 51.02% 的潜在上涨空间。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>药明康德的股票能否满足华尔街的高期望？</li>
</ul>
</div><p>A number of other equities research analysts also recently issued reports on the stock. Wolfe Research set a $95.00 price objective on shares of BioMarin Pharmaceutical and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, July 15th. Wall Street Zen cut shares of BioMarin Pharmaceutical from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. The Goldman Sachs Group dropped their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, May 5th. Morgan Stanley reduced their target price on BioMarin Pharmaceutical from $97.00 to $96.00 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, July 22nd. Finally, JPMorgan Chase &amp; Co. increased their price objective on shares of BioMarin Pharmaceutical from $108.00 to $113.00 and gave the stock an &#34;overweight&#34; rating in a research report on Monday, July 14th. Six equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $93.78.</p>
<div class="lb-trans"><p>其他一些股票研究分析师最近也对该股票发布了报告。Wolfe Research 在 7 月 15 日的研究报告中对药明康德的股票设定了 95.00 美元的价格目标，并给予公司 “跑赢大盘” 的评级。Wall Street Zen 在 7 月 18 日的研究报告中将药明康德的股票评级从 “强力买入” 下调至 “买入”。高盛集团在 5 月 5 日的研究报告中将药明康德的股票目标价从 124.00 美元下调至 104.00 美元，并给予公司 “买入” 评级。摩根士丹利在 7 月 22 日的报告中将药明康德的目标价从 97.00 美元下调至 96.00 美元，并给予公司 “增持” 评级。最后，摩根大通在 7 月 14 日的研究报告中将药明康德的股票目标价从 108.00 美元上调至 113.00 美元，并给予该股票 “增持” 评级。六位股票研究分析师对该股票给予了持有评级，十九位分析师给予公司买入评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 93.78 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BMRN</strong></p>
<div class="lb-trans"><p><strong>获取我们对 BMRN 的最新股票分析</strong></p>
</div><h2>BioMarin Pharmaceutical Price Performance</h2>
<div class="lb-trans"><h2>药明康德的价格表现</h2>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
</div><p>BMRN traded up $1.93 during trading on Tuesday, reaching $62.24. 1,233,643 shares of the stock were exchanged, compared to its average volume of 1,887,433. The company has a market capitalization of $11.94 billion, a price-to-earnings ratio of 23.21, a P/E/G ratio of 0.80 and a beta of 0.18. BioMarin Pharmaceutical has a 1 year low of $52.93 and a 1 year high of $94.85. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.52 and a quick ratio of 3.49. The business's 50 day moving average price is $57.16 and its two-hundred day moving average price is $61.79.</p>
<div class="lb-trans"><p>周二，BMRN 的交易价格上涨了 1.93 美元，达到 62.24 美元。该股票的交易量为 1,233,643 股，而其平均交易量为 1,887,433 股。该公司的市值为 119.4 亿美元，市盈率为 23.21，市盈率/增长比率为 0.80，贝塔值为 0.18。药明康德的 1 年最低价为 52.93 美元，1 年最高价为 94.85 美元。该公司的债务与股本比率为 0.10，流动比率为 5.52，速动比率为 3.49。该公司的 50 日移动平均价格为 57.16 美元，200 日移动平均价格为 61.79 美元。</p>
</div><h2>Insider Transactions at BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>药明康德的内部交易</h2>
</div><p>In related news, CAO Erin Burkhart sold 1,786 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total transaction of $105,927.66. Following the completion of the sale, the chief accounting officer owned 14,173 shares of the company's stock, valued at $840,600.63. The trade was a 11.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席会计官 Erin Burkhart 在 5 月 20 日的交易中出售了 1,786 股药明康德的股票。该股票以平均价格 59.31 美元出售，总交易额为 105,927.66 美元。出售完成后，首席会计官持有该公司 14,173 股股票，价值 840,600.63 美元。此次交易使其持股减少了 11.19%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。内部人士持有该公司 0.85% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
</div><p>A number of hedge funds have recently bought and sold shares of the company. Rise Advisors LLC purchased a new position in BioMarin Pharmaceutical during the first quarter valued at $30,000. Farther Finance Advisors LLC grew its stake in BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after buying an additional 211 shares during the period. V Square Quantitative Management LLC bought a new position in BioMarin Pharmaceutical in the 2nd quarter valued at about $25,000. LRI Investments LLC boosted its stake in shares of BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 437 shares in the last quarter. Finally, MassMutual Private Wealth &amp; Trust FSB lifted its position in BioMarin Pharmaceutical by 71.2% during the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 218 shares during the period. 98.71% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了该公司的股票。Rise Advisors LLC 在第一季度购买了药明康德的新头寸，价值 30,000 美元。Farther Finance Advisors LLC 在第一季度将其在药明康德的股份增加了 95.9%。Farther Finance Advisors LLC 现在拥有 431 股该生物技术公司的股票，价值 29,000 美元，此前在该期间又购买了 211 股。V Square Quantitative Management LLC 在第二季度购买了药明康德的新头寸，价值约 25,000 美元。LRI Investments LLC 在第四季度将其在药明康德的股份增加了 856.9%。LRI Investments LLC 现在拥有 488 股该生物技术公司的股票，价值 32,000 美元，此前在上个季度又购买了 437 股。最后，MassMutual Private Wealth &amp; Trust FSB 在第一季度将其在药明康德的股份增加了 71.2%。MassMutual Private Wealth &amp; Trust FSB 现在拥有 524 股该生物技术公司的股票，价值 37,000 美元，此前在该期间又购买了 218 股。98.71% 的股票目前由机构投资者持有。</p>
</div><h2>About BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p>
<div class="lb-trans"><p>药明康德公司开发和商业化针对严重和危及生命的罕见疾病及医疗状况的治疗方案。其商业产品包括 Vimizim，一种用于治疗粘多糖贮积症（MPS）IV 型 A 的酶替代疗法；Naglazyme，一种用于 MPS VI 患者的重组 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的专有合成口服 6R-BH4。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>Following Congress Stock Trades</li>
<li>Figma's Wild IPO Ride: Is the Stock's Premium Price Justified?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>META Gets Huge Upgrades: How High Analysts Think Shares Could Go</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过药明康德</li>
<li>国会股票交易跟踪</li>
<li>Figma 的疯狂 IPO 之旅：股票的溢价价格是否合理？</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>META 获得巨大升级：分析师认为股票可能上涨多少</li>
<li>投资旅游股票的好处</li>
<li>诺和诺德股票下跌——但是否终于触底？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BMRN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而拜玛林制药并不在名单上。</p>
</div><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然拜玛林制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Wedbush 重申对 BioMarin Pharmaceutical（BMRN）的 “跑赢大盘” 评级